Abstract
Introduction Most countries worldwide have experienced excess mortality that coincides temporally with the COVID-19 mass vaccination campaigns. This has led to speculation on the potential long-term effects of the vaccines on mortality risk.
Methods The study was designed as a retrospective cohort study, and included all individuals aged ≥18 years living in Norway during January 1, 2021, through December 31, 2023. Individuals were categorized as either unvaccinated (received no doses), partially vaccinated (received one or two doses) or fully vaccinated (received three or more doses) from the date of vaccination and onwards. Age-stratified Poisson models were used to estimate incidence rate ratios of death (all causes) between vaccination groups, adjusting for sex, calendar time, county of residence and risk group status (nursing home resident or preexisting condition with increased risk of severe COVID-19).
Results The study included 4 645 910 individuals (49.8% women) with 132 963 deaths during follow-up. There was a higher proportion of individuals that were part of a risk group among fully vaccinated individuals compared to unvaccinated individuals in all age groups, and a lower unadjusted rate of death: 51.5 vs 73.6 per 100 000 person years (py) among individuals aged 18-44 years, 295.1 vs 405.3 per 100 000 py among 45-64 years, and 3620.2 vs 4783.8 per 100 000 py among 65 years or older. The adjusted IRR of death for the same age groups were 0.42 (95% CI 0.38-0.47), 0.39 (95% CI 0.37-0.41) and 0.42 (95% CI 0.41-0.43), respectively. The differences in rate of death between vaccination groups were larger among men and peaked during 2022.
Conclusion Vaccinated individuals had a lower rate of all-cause death during 2021-2023 in Norway.
Key messages In Norway, as in many Western countries, there has been an excess mortality during 2021-2023, surpassing the numerical count of COVID-19-associated deaths. The excess mortality coincides temporally with the COVID-19 mass vaccination campaigns, but longitudinal data regarding mortality post-vaccination remain sparse. Using real-time national health registry data, we estimate the risk of all-cause mortality by vaccination status in the total adult population in Norway during 2021-2023 and demonstrate a lower rate of all-cause death among vaccinated individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was obtained for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Committee for Medical and Health Research Ethics South-East Norway (REK South East A, ref 122745)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data sharing
Owing to data privacy regulations in Norway, the raw data cannot be shared. However, the data are available for research upon reasonable request to The Norwegian Institute of Public Health after approval from the Norwegian Committee for Medical and Health Research Ethics and within the framework of the Norwegian data protection legislation and any required permission from Authorities.
